Chris A. Rallis - 11 May 2026 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Reporting relationship: Director
Issuer ticker: FENC
Reported as of: 11 May 2026
Net transaction value: -$58,756
SEC form: 4
Accepted by SEC: 12 May 2026, 16:05:17 UTC
Prior SEC filing: 14 Oct 2025
Next SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Chris Rallis

Key filing fact

Chris A. Rallis filed Form 4 for FENNEC PHARMACEUTICALS INC. (FENC) on 12 May 2026.

Key facts

This page summarizes Chris A. Rallis's Form 4 filing for FENNEC PHARMACEUTICALS INC. (FENC).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 May 2026, 16:05.

Change

Previous filing in this sequence was filed on 14 Oct 2025.
Current net transaction value: -$58,756.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001185945 Primary reporting owner

RALLIS CHRIS A

Relationship: Director
Address: C/O FENNEC PHARMACEUTICALS, INC., PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK
Signature: /s/ Chris Rallis
Signature date: 12 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FENC transaction

Common Shares

Options Exercise

Transaction value
Shares: +14,344
Change %: +25%
Price: $2.44^*
Shares after: 71,423
Date: 11 May 2026
Ownership: Direct
Footnotes: F1

FENC transaction

Common Shares

Sale

Transaction value: $58,756
Shares: -8,346
Change %: -12%
Price: $7.04
Shares after: 63,077
Date: 11 May 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FENC transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares: -14,344
Change %: -7.2%
Price: $2.44^*
Shares after: 186,189
Date: 11 May 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 14,344
Exercise price: $2.44
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on May 19, 2025.

Footnote F2

Shares sold to satisfy tax obligation on option exercise.

Footnote F3

Represents options exercised pursuant to a 10b5-1 plan adopted on May 19, 2025.